Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks
Year: 2026
Type: article
Study design: Observational Study
Abstract: Subcutaneous (SC) vedolizumab offers practical advantages over intravenous (IV) administration, but real-world data on switching established patients from IV to SC maintenance therapy remain limited, particularly beyond 12 months. This single-centre, retrospective cohort study evaluated 24 adults with inflammatory bowel disease (IBD) who transitioned from IV to SC vedolizumab maintenance therapy between August 2020 and October 2023. Clinical disease activity indices (SCCAI, HBI), biochemical markers (C-reactive protein, faecal calprotectin) and treatment persistence were assessed at weeks 12, 24 and 48. The cohort comprised 10 patients with Crohn’s disease, 12 with ulcerative colitis and 2 with indeterminate IBD. Treatment persistence was 100% at week 12, 92% at week 24 and 71% at week 48; seven patients (29.2%) discontinued, most often for loss of response ( n = 4). Among continuers, clinical and biochemical disease activity remained stable, and median faecal calprotectin was unchanged across timepoints. No serious adverse events or systemic hypersensitivity reactions were documented; one patient had an injection-site reaction prompting return to IV therapy. In this small, single-centre retrospective cohort, switching from IV to SC vedolizumab was associated with acceptable persistence and stable disease control in appropriately selected patients, particularly those in remission at the time of switch.
Source: npj Autoimmunity
Authors: Omar Salehi(Conceptualization, Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing), Andrew Chen(Data curation, Formal analysis, Writing – review & editing), Faris Gondal(Data curation, Investigation, Writing – review & editing), Weilun Gao(Data curation, Investigation, Writing – review & editing), Clarissa Rentsch(Data curation, Investigation, Writing – review & editing), Stephanie Dimovski(Data curation, Investigation, Writing – review & editing), Finlay Macrae(Conceptualization, Supervision, Writing – review & editing), Jonathan P. Segal(Conceptualization, Methodology, Supervision, Writing – review & editing)
Institutions: The Royal Melbourne Hospital, Austin Hospital
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: vedolizumab, subcutaneous administration, inflammatory bowel disease, Crohn's disease, ulcerative colitis, maintenance therapy, treatment persistence, loss of response, fecal calprotectin, C-reactive protein, disease activity, injection site reactions, real-world effectiveness, drug safety
Open Access status: hybrid
OpenAlex ID: W7161602792
